Brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are novel natriuretic peptides, originally isolated from porcine brain. Similar to atrial natriuretic peptide (ANP), BNP is also synthesized in and secreted from cardiocytes, but CNP is not expressed at significant levels in normal adult myocardium. Previous studies have indicated that the serum level and ventricular expression of the ANP gene were augmented in patients with heart failure. Recently, the serum level of BNP was also reported to increase in human heart failure. To examine whether or not the expression of these natriuretic peptides is regulated in ventricular myocardium in a concordant manner, we performed Northern blot analysis using total cellular RNA isolated from the diseased left ventricles of 30 cardiac transplant recipients with end-stage heart failure, seven ventricles from organ donors (control group), and two ventricles of artificially aborted 17-and 19-week-old fetuses. The levels of mRNAs encoding both BNP and ANP increased significantly (p<0.01) in the left ventricular myocardium from the patients with end-stage heart failure as compared with the control group. The levels of BNP mRNA correlated positively with those of ANP mRNA (r=0.73, p<0.01) and negatively with those of sarcoplasmic reticulum Ca2'-ATPase mRNA (r= -0.66,p<0.01) in the left ventricular myocardium from the patients with heart failure. There was also a negative correlation between the levels of ANP and the sarcoplasmic reticulum Ca2'-ATPase mRNAs (r= -0.65, p<0.01). In fetal myocardium, ventricular expression of ANP mRNA was higher and that of BNP mRNA was unchanged as compared with adult control myocardium. In contrast, CNP mRNA was not detectable by Northern blot analysis in either the normal, fetal, or diseased ventricular myocardium. These data suggest that ventricular expression of BNP and ANP mRNAs is concordantly regulated in patients with end-stage heart failure and that this coexpression of these two natriuretic peptides may play an important role in a compensatory process in human heart failure. In contrast, expression of BNP and ANP is discordantly regulated in the fetal ventricles, and CNP is probably never expressed at the significant level detectable by Northern blot analysis in the ventricles either during development or in disease states. (Circulation Research 1992;71:9-17 
B rain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are novel natriuretic peptides recently isolated from porcine brain.12 Similar to atrial natriuretic peptide (ANP), BNP has potent diuretic-natriuretic and vasorelaxant activities selectively activates the B-type natriuretic peptide receptors but has little effect on the A-type receptors. 20 In normal humans, circulating ANP is produced almost exclusively by the atria. On the other hand, synthesis and secretion of ANP from the ventricles were found to be markedly augmented in patients21-27 and animal models2128-33 with ventricular hypertrophy or failure. The ventricular expression of ANP has also been shown to be high in fetal22 and neonatal29,34 ventricles. Recently, the plasma level of BNP was reported to be elevated in patients with heart failure,10 and the ventricular expression of BNP gene was found to be augmented in a very small number of patients. 10, 35 These increases in plasma levels and in ventricular secretion of both ANP and BNP were shown to correlate well with the severity of heart failure.10,23 Furthermore, recent studies demonstrated that an intravenous injection of ANP36,37 or BNP38 significantly improved cardiac performance in patients with heart failure. These data altogether suggest that the augmented ventricular expression of ANP and BNP may play compensatory roles in human heart failure. The increased ventricular expression of ANP in the fetal right ventricles might also be an adaptational process to hemodynamic requirements during development. 22 However, it is still unknown whether or not expression of these two natriuretic peptides is regulated in a concordant manner in disease states and during development of human ventricular myocardium. Nor is it known whether CNP expression is augmented in failing ventricles.
To address these questions, we analyzed RNA isolated from ventricular myocardium of cardiac transplant recipients, organ donors, and artificially aborted fetuses using synthetic oligonucleotide probes specific for ANP, BNP, and CNP. We also correlated the levels of mRNAs encoding the natriuretic peptide genes to those of the sarcoplasmic reticulum Ca2'-ATPase mRNA, which is known to be significantly downregulated in the failing human myocardium. 39 
Materials and Methods

Subjects
We analyzed the data from 30 patients (27 Figure 1 shows the results of a representative Northern blot analysis using the specific DNA probes. The BNP probe detected a single mRNA species of approximately 0.9 kb in the left ventricular myocardium from the patients with end-stage heart failure ( Figure 1 (Figure 1 , fourth row). As compared with the normal adults, the ventricular levels of this mRNA species were significantly lower in patients with heart failure. Interestingly, the levels of the sarcoplasmic reticulum Ca2'-ATPase were also very low in the fetal hearts. The GAPDH probe hybridized with a single mRNA species of approximately 1.6 kg ( Figure 1 , fifth row). The ventricular levels of mRNA encoding this glycolytic pathway enzyme were not different between the patients with end-stage heart failure and the adult normal controls but were quite low during the fetal stage. Figure 2 shows the results of laser densitometric determination of the relative abundance of BNP and ANP mRNAs in the adult left ventricles. The densitometric scores were normalized by the relative abundance of GAPDH mRNA as an internal control. The mean value of the normalized scores of the normal control group was arbitrarily set as 1.0. The left ventricular levels of mRNA encoding BNP were significantly (p<0.01) higher in patients with end-stage heart failure (6.6+5.1; range, 1.1-17.7) than in the normal control group (1.0+0.3; range, 0.6-1.5). The patients with idiopathic dilated cardiomyopathy and those with coronary artery disease (isehemic cardiomyopathy) showed significantly (both p<0.01) higher ventricular levels of BNP mRNA than did the normal control group. The left ventricular expression of ANP mRNA was also (Figure 3 ).
As shown in Figure 2 , the left ventricular levels of both BNP and ANP mRNAs were highly variable in end-stage heart failure. There was, however, a significant positive correlation (r=0.73, p<0.01) between the relative levels (expressed as the percentage of the maximal values observed in the patients) of mRNAs encoding BNP and ANP (Figure 4 ). This positive correlation suggests that expression of these two natriuretic peptides may be concordantly regulated in the failing left ventricular myocardium. The correlation coefficients between the levels of BNP and ANP mRNAs were comparable between patients with ischemic cardiomyopathy (r=0.72, p<0.01) and those with idiopathic dilated cardiomyopathy (r=0.70,p<0.01).
Furthermore, we found a significant negative correlation between BNP and the sarcoplasmic reticulum Ca2'-ATPase mRNAs (r= -0.66, p<0.01) in these patients ( Figure SA) . A similar correlation (r=-0.65, p<0.01) was also found between ANP and the sarcoplasmic reticulum Ca2+-ATPase mRNAs ( Figure 5B It has been shown that a small but detectable level of BNP is secreted from the rat heart9 and normal human ventricles.10 The heart, not the brain, is likely to be the major source of the circulating BNP in normal subjects. Mukoyama et al10 recently reported that plasma levels of human BNP were significantly higher in patients with heart failure than in normal control subjects. The levels of plasma BNP were even higher than those of ANP in some patients.10 They demonstrated that the increased SR Ca2+ -ATPase secretion from the ventricles appeared to be the major source of the augmented plasma levels of BNP in the patients with heart failure.10 Ventricular expression of BNP was also shown to increase at mRNA levels in previous studies with a very limited number of patients (only two, one with dilated cardiomyopathy and one with hypertrophic cardiomyopathy).10,35 Our present study extends the results of these studies by using a much larger number of patients with end-stage heart failure. In addition, there are some differences between the previous studies1035 and ours. First, ventricular expression of BNP mRNA in their normal control group1035 appears to be significantly higher than it is in ours. This difference may be attributable to the differences in the ages of the control group and the origin of the "normal" ventricular samples. They obtained ventricular samples from autopsies of aged patients in whom ventricular expression of BNP mRNA could be augmented, either from the stress of terminal events or from aging-associated myocyte hypertrophy. In contrast, all of our myocardial samples were freshly obtained at the time of organ transplant. Second, because of the limited number (n =2) of the subjects, the previous studies10'35 could not determine the relations between the ventricular mRNA levels of BNP and those of ANP in the diseased states. Third, we were able to correlate the left ventricular expression of the natriuretic peptide genes with that of another cardiac gene, the sarcoplasmic reticulum Ca'+-ATPase gene, in the same patients. Finally, we have demonstrated that, unlike ANP, the BNP gene is not expressed at high levels in the fetal ventricles, although we cannot rule out a possibility of significant BNP expression in the late fetal stage or early childhood.
Recently, the human BNP gene was cloned and sequenced.15 In the 5' upstream region of the human BNP gene, sequences similar to the atrial-specific element (-409 to -332-bp upstream of the transcription start site) of the human ANP gene45 were not present, suggesting that the tissue specificity of the human BNP gene transcription may be under different control from that of the human ANP gene. The BNP cDNA has repeat sequences of TATTTAT in its 3' untranslated region,13-1'but these repeated sequences are not found in the ANP cDNA. These characteristic sequences are suggested to confer mRNA instability in some transcripts46 and may be important in regulating the level of BNP mRNA. These sequence differences between the BNP and ANP genes may suggest that the expression of these two genes is regulated differently.15 The differences in ventricular expression of BNP and ANP mRNAs during the fetal stage (the present study) and a lower expression of BNP in the adult atrium38-'0 are among the notable differences between these genes. However, the significant positive correlation between the mRNA levels of these peptides suggests that there may at least exist some common molecular mechanisms for the regulation of the ventricular expression of the BNP and ANP genes in human heart failure. Recently, Yokota et al47 reported a highly significant positive correlation between the immunoreactive levels of BNP and ANP in the ventricles of deoxycorticosterone acetate-salt hypertensive rats. The results of this experimental study are in agreement with our human study and support the notion that there should be some common mechanisms in regulating expression of these peptide genes in the diseased ventricles.
The pathophysiological significance of the augmented plasma levels of BNP may be similar to that of ANP.
The plasma levels of BNP'0 and ANP23 are correlated with the severity of heart failure. Ca2'-ATPase protein might lead to a prolongation of myocardial contraction and a decrease in ATP consumption as well as tension-independent heat generation in the cardiac muscles and that these alterations could be beneficial for hypertrophied myocardium. Although the previous studies39'48-50 also suggested that the depressed Ca2'-ATPase expression might contribute to diastolic dysfunction in cardiac hypertrophy and failure, it is possible that the concomitant changes in the natriuretic peptides and the sarcoplasmic reticulum
Ca2'-ATPase in concert may play compensatory roles in human heart failure. The roles of BNP and ANP during the developmental stage are still unknown. The dissociation between the levels of BNP and ANP mRNAs in the fetal ventricles suggests that these two natriuretic peptides may play different roles during development. It has been shown that ventricular expression of ANP is the highest in the subendocardial region of the fetal right ventricles.22 It has been suggested that the augmented expression of ANP appears to occur in the region subjected to the maximal hemodynamic stress during the fetal stage and may also be a compensatory mechanism just as in heart failure.22 However, the different patterns of BNP and ANP expression in the failing and fetal ventricular myocardium may be opposed to this hypothesis. At least some developmental stage-specific factors may be necessary in the regulation of ventricular expression of these natriuretic peptides, in addition to the hemodynamic stress.
We noted no detectable expression of CNP mRNA by Northern blot analysis in any of the ventricles studied. There has been no report that circulating CNP peptide levels are elevated, either in experimental cardiac overload or in patients with heart failure. CNP is known to have much less potent natriuretic effects when injected in animals,2 and it is possible that CNP is expressed and functions only in the central nervous system.
We did not attempt to correlate the mRNA data with hemodynamic parameters because of the significant delay (mean, 4.7 months; range, 0.3-20 months) between the hemodynamic measurements and cardiac transplant surgery. Thus, further studies will be needed to clarify hemodynamic determinants of the altered expression of ANP, BNP, and the sarcoplasmic reticulum Ca2+-ATPase mRNAs in failing human left ventricles.
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